Truveta Raises $320M to Sequence 10M Exomes and Build Largest Genetic Database
The health data company Truveta, in collaboration with Regeneron and Illumina, and 17 major U.S. health systems, has launched the …
All Posts
Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases
Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory …
Bayer's Cell Therapy for Replacing Dopamine Neurons in Parkinson’s Advances to Phase III
Bayer, through its subsidiary BlueRock Therapeutics, has announced plans to advance bemdaneprocel (BRT-DA01), its investigational pluripotent stem cell-derived dopaminergic neuron therapy …
Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation
Atropos Health has announced a collaboration with Merck to utilize its suite of tools for real-world evidence (RWE) generation, including …
Sana Reports Promising Results for Type 1 Diabetes Islet Cell Transplants Without Immunosuppression
Sana Biotechnology announced promising early results from a first-in-human study of its hypoimmune (HIP) technology for type 1 diabetes. Conducted …
Verdiva Bio Launches With $411M to Propel Weekly-Dosed GLP-1 Obesity Drug
Verdiva Bio has launched with $411 million in Series A financing, reportedly one of the largest early-stage funding rounds for …
Insilico Medicine Licenses Second AI-Generated Cancer Drug Candidate in a $550M Deal
Insilico Medicine and Menarini Group’s Stemline Therapeutics have announced a second exclusive licensing agreement for an AI-discovered oncology drug candidate. …
Eli Lilly Partners with UK’s Alchemab to Develop New ALS Antibodies
Eli Lilly has partnered with UK-based biotech Alchemab Therapeutics to develop therapeutic antibodies targeting amyotrophic lateral sclerosis (ALS), a neurodegenerative …
What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025
In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech …
Discovery of Novel Longevity Therapeutics that Target Mitochondrial Enzymes
Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the …
Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform for Preclinical Drug Safety Testing
Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety …
PostEra and Pfizer Expand $610M Partnership for AI-Driven ADC Development
PostEra, Boston biotech specializing in AI-driven drug discovery, announced an expansion of its collaboration with Pfizer, increasing the total partnership …